A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Intermediate or High-risk Prostate Cancer
Latest Information Update: 30 May 2025
At a glance
- Drugs Darolutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms COAction
Most Recent Events
- 30 May 2025 Last checked against ClinicalTrials.gov record.
- 23 May 2025 Status changed from not yet recruiting to recruiting.
- 10 Oct 2024 New trial record